South Africa Contraceptive Devices Market Analysis Sample Report

1. A sample report on South Africa Contraceptive Device Market Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

2. This report presents a strategic analysis of the South Africa Contraceptive Device Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point- of-care testing, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the South Africa Contraceptive Device Market, and offers unmatched value, accuracy, and expert insights

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

4. Table of Content CONTENT PG. NO. 12-25 1. Contraceptive Device Overview 1.1. Overview 1.2. South Africa Overview 1.3. Economic Overview: South Africa 1.4. Contraceptive Device Market in South Africa 1.5. Medical Devices Market in South Africa 1.6. Healthcare Scenario in South Africa 1.7. Health Insurance Coverage: South Africa 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 26-30 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. By Type 2.2.2. By Gender 31-35 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. South Africa Contraceptive Device Market Driver 1 3.1.2. South Africa Contraceptive Device Market Driver 2 3.1.3. South Africa Contraceptive Device Market Driver 3 3.2. Market Restraints 3.2.1. South Africa Contraceptive Device Market Restraint 1 3.2.2. South Africa Contraceptive Device Market Restraint 2 5 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

6. Table of Content CONTENT PG. NO. 3.2.3. South Africa Contraceptive Device Market Restraint 3 36-46 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Bayer 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. Medtronic 4.2.2.1. Overview 6 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

7. Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Femcare-Nikomed 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. Evofem Biosciences 4.2.4.1. Overview 7 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

8. Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. Disa Vascular 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. Marie Stopes South Africa 4.2.6.1. Overview 8 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

9. Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Charmeuse Biotech 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. Adcock Ingram 4.2.8.1. Overview 9 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

10. Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Safripol 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. Aceso Medical 4.2.10.1. Overview 10 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

11. Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 47-54 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 5.4 Reimbursement Process – Medicare 5.5 Reimbursement Process - Medicaid 55-74 6. Methodology & Scope 11 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

12. South Africa Contraceptive Device Market Analysis 1. Contraceptive Device Overview

13. 1.1 Statistics at a Glance: The Unintended Pregnancy Cases in the World (1/2) Global figures of Unintended Pregnancy Cases & Contraception Use Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 121 Mn Pregnancies are unintended each year throughout the world 257 million Women globally who want to avoid pregnancy are not using safe, modern methods of contraception In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ In 47 countries, 40% of sexually active women were not using any contraceptive methods to avoid pregnancy in 2022 Over 60% of unintended pregnancies, and almost 30% of all pregnancies, end in abortion In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Out of 1.9 Bn Women of Reproductive Age group (15-49 years) worldwide in 2019, 1.1 Bn have a need for family planning; of these, 842 Mn are using contraceptive methods, and 270 Mn have an unmet need for contraception 13 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

14. 1.1 Statistics at a Glance: The Unintended Pregnancy Cases in the World (2/2) Europe ~Revenue to reach $xx Bn by 2027 North America ~ Market Size of $xx Bn Asia ~$xx Mn Market Africa Egypt Market ~$xx Mn Market ~Market Size of $xx Bn Illustrative Illustrative 14 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

15. 1.2 South Africa Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 60.15 Mn Is the population of South Africa, in 2022 $300 Bn Is the Gross Domestic Product (GDP) in South Africa in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 27 years Is the median age in South Africa, in 2022 $547 per capita was the amount of national health expenditures in 2022 This Photo by Unknown Author is licensed under CC BY-SA Illustrative Illustrative 15 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

16. 1.3 Economic Overview: South Africa Population of South Africa, (2020-2030) GDP of South Africa, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

17. 1.4 Statistics at a Glance: The Unintended Pregnancy Cases in South Africa South Africa figures of Unintended Pregnancy Cases & Contraception Use Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 51% women aged 15-49 years in South Africa used contraceptives in 2021 80% young women and girls in South Africa have easy access to contraceptives In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in South Africa ▪ South Africa has the highest contraceptive prevalence rate in entire Africa in 2021 54% Was South Africa’s couple year protection rate (CYPR) in 2019-20 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 47.9% Is the prevalence of modern contraceptive use in South Africa 70% Of contraceptives claimed through the Discovery Health Scheme in the past three years were contraceptive pills, such as Yaz and Qlaira Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 17 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

18. 1.5 Medical Devices in South Africa South Africa Medical Devices Market Forecast, 2022-2030 (in $Bn) xx xx xx xx xx xx xx xx xx 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Medical Devices market in South Africa, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

19. 1.6 Healthcare Scenario in South Africa Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

20. 1.6 Healthcare Scenario: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 20 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

21. 1.7 Health Insurance Coverage: South Africa % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 21 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

22. 1.8 Budget of South Africa Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% oftotal NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

23. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

24. 1.9 Mergers and Acquisitions (continued) Latest Deals In South Africa Amount / Duration Company Name Type Year Key Pointers South African e-health startup Quro Medical has raised ZAR25 million (US$1.3 million) in funding from the Mineworkers Investment Company (MIC) The startup is building the largest virtual hospital ward in Africa, which seeks to achieve superior clinical outcomes to conventional care at a lower cost Quro Medical’s platform reduces the costs of healthcare delivery by leveraging real-time, data-driven clinical interventions ▪ ▪ Fund raise $1.3 Mn May 2023 Quro Medical ▪ Mediclinic Southern Africa division received approval for its proposed acquisition of a controlling share in Matlosana Medical Health Services Proprietary Limited ▪ It is based in Klerksdorp in the North-West Province of South Africa ▪ Acquisition $xx Bn Feb 2020 Mediclinic The acquisition includes two multi-disciplinary hospitals namely the 185-bed Wilmed Park Hospital and the 62-bed Sunningdale Hospital ▪ Illustrative Illustrative 24 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

25. 1.9 Mergers and Acquisitions(continued) Latest Deals In South Africa Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 Illustrative Illustrative 25 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

26. South Africa Contraceptive Device Market Analysis 2. Market Size and Forecasting

27. 2.1 Market Size and Forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption South Africa Contraceptive Devices Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Malaysia Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Malaysia Market Size (Bn $) 61 74 84 87 91 95 99 106 Illustrative Illustrative 27 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

28. 2.2 Snapshot of South Africa Contraceptive Device Market Segmentation By Type By Gender Condoms Males Diaphragms Females Cervical Caps Sponges Vaginal Rings Intra Uterine Device In this section you will get an understanding of the segmentations which will cover the South Africa Contraceptive Device Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 28 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

29. 2.2.1 Market Segmentation: By Type South Africa Contraceptive Device Market Share, By Type (2022) Condoms market in South Africa is a significant component of the overall Contraceptive devices market ▪ Intra Uterine Device It has the maximum market share in South Africa cancer market with approximately xx% ▪ Vaginal Rings Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Sponges Condoms Cervical Caps In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Diaphragms Illustrative Illustrative 29 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

30. 2.2.2 Market Segmentation: By Gender South Africa Contraceptive Device Market Share, By Gender (2022) Male market in South Africa is a significant component of the overall contraceptive market ▪ It has the maximum market share in South Africa cancer market with approximately xx% ▪ Female Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Male Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interestIllustrative ▪ Illustrative 30 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

31. South Africa Contraceptive Device Market Analysis 3. Market Dynamics

32. 3.1 Market growth drivers 3.1.1 Incidence of cancer is increasing in South Africa, with more than 1.8 Mn new cancer cases expected to be diagnosed in 2023 Incidence of cancer is increasing in South Africa, with more than 1.8 Mn new cancer cases expected to be diagnosed in 2023 ▪ Incidence of Cancer in South Africa This is driving the demand for cancer treatments and creating opportunities for growth in the cancer market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 32 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

33. 3.1 Market growth drivers (continued) 3.1.2 Death rate from cancer in South Africa has declined by 31% from 1992 to 2022, largely due to advances in technology and treatment options Top countries that are leveraging technology in their fight against cancer South Africa has a long history of investing in cancer research and treatment, and as a result, has become a world leader in the field ▪ Norway IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to cancer treatment and research ▪ Austria Denmark Belgium Spain One of the key factors that has allowed South Africa to stay ahead in the field of cancer research and treatment is the high level of investment in cancer-related research ▪ Italy Netherlands Sweden Singapore Switzerland In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Israel Australia Canada Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ France United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 33 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

34. 3.1 Market growth drivers (continued) 3.1.3 In 2021, the National Cancer Institute (NCI) received $6.4 Bn in funding from South Africa federal government to support cancer research and training programs Fundings from government and other organizations South Africa government provides significant support and funding for cancer research and treatment, which is driving innovation and growth in the cancer market ▪ Source Year Fund ($) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ National Cancer Institute (NCI) 2021 $ 6.4 Bn In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Centers for Disease Control and Prevention (CDC) 2021 $ 501 Mn Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ American Cancer Society (ACS) 2020 $ 150 Mn Susan G. Komen 2020 $ 98 Mn Illustrative Illustrative 34 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

35. 3.2 Market restraints 3.2.1 In 2020, the average cost of a new cancer drug was over $150,000 per year 3.2.2 Average cost of developing a new cancer drug that is ultimately approved by the FDA is over $2.6 Bn 3.2.3 Demand for cancer care is expected to increase by 42% by 2025, while the supply of oncologists is only expected to increase by 28% Cancer treatments can be very expensive and can lead to financial burden for patients and healthcare systems Cost of cancer treatment varies depending on the type of cancer, stage of cancer, and treatment options Some common cancer treatments, such as chemotherapy and radiation therapy, can cost tens of thousands of dollars Regulatory requirements for cancer treatments can be very stringent, which can slow down the approval process and limit access to new treatments Regulatory bodies, such as South Africa Food and Drug Administration (FDA), require extensive clinical trials and safety data before approving new cancer treatments This can be a lengthy and costly process, which can delay the availability of new treatments for patients There is a shortage of oncologists in South Africa, which can limit access to cancer treatments and create barriers to growth in the cancer market Oncologists are physicians who specialize in the diagnosis and treatment of cancer With the aging population and the increasing incidence of cancer, there is a growing demand for oncologists However, the supply of oncologists is not keeping pace with the demand ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 35 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

36. South Africa Contraceptive Device Market Analysis 4. Competitive Landscape

37. 4.1 Major Market Share Revenue of Major players in South Africa Cancer Market ($ Mn) South Africa contraceptive market is a highly competitive space, with many companies developing and marketing cancer treatments ▪ Other Some of the top companies in South Africa cancer market based on revenue and market share include ▪ Bayer is a Swiss multinational healthcare company that develops and markets cancer treatments, including targeted therapies and immunotherapies ▪ In 2020, Bayer's oncology sales were approximately $24 Bn, making it one of the largest players in South Africa cancer market ▪ XX Illustrative Illustrative 37 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

38. 4.2 Key Company Profile Key Note: 1 Bayer Here is the list of top 10 companies which will cover in the final report ▪ 2 Medtronic Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Femcare-Nikomed o o 4 Evofem Biosciences o o 5 Disa Vascular o Marie Stopes South Africa 6 o o 7 Charmeuse Biotech o 8 Adcock Ingram ▪ 9 Safripol ▪ 10 Aceso Medical 38 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

39. 4.2.1 Bayer SA Founded in: 1993 Main divisions of Bayer SA ▪ Bayer South Africa is a subsidiary of Bayer AG, a multinational pharmaceutical and life sciences company ▪ Pharmaceutical division of the company has been active for over 50 years with its activities focused on Women’s Healthcare, Cardiology, Oncology, Hematology and Ophthalmology ▪ By 2030, it is committed to providing 100 million women in low- and middle-income countries with access to modern contraception. HQ: Johannesburg, SA ➢ Crop Science Type: Private ➢ Pharmaceuticals Revenue: $45.5 Bn ➢ Consumer Health Website: www.bayer.co.za Contraceptive options Recent Activity / Press Coverage Device Key feature Bayer’s contraceptive products including pills, injectables, intrauterine devices (IUD), intrauterine systems (IUS) and implants were used by around 40 million women in LMICs in 2020 Long-acting reversible contraceptive (LARC) implant Implanon Mirena Intrauterine device (IUD) Bayer is currently advancing approximately 50 projects through the clinic, especially in areas of high unmet medical need. Jaydess Intrauterine device (IUD) Copper IUDs Non-hormonal contraceptive devices 39 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

40. 4.2.1 Bayer (continued) Partnerships Ecosystem Major Partnerships Major Collaborative Partners ▪ To enable research to accelerate and innovate in the field of non-hormonal contraception ▪ Bayer & DareBio Sciences have license agreement under which Bayer may commercialize Daré’s investigational contraceptive product, Ovaprene in the United States once approved by the FDA ▪ The initiative has the potential to benefit woman in Low- and Lower-Middle- Income Countries (LLMICs) ▪ The initiative by Bayer & White Ribbon Alliance, which was launched in 2015 and renewed till 2023 ▪ Merck had worldwide collaboration with bayer to market and develop novel therapies for cardiovascular disease ▪ It focuses on using self-care to improve maternal, infant and child health, reaching the most vulnerable individuals in underserved countries ▪ Collaboration Included a $1 Bn Up-front Payment by Merck to Bayer 40 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

41. 4.2.1 Bayer (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Bayer, together with the Bill & Melinda Gates Foundation, are jointly funding pre-clinical research in the area of novel non- hormonal contraception ▪ Grant $ 12 Mn October 2022 Bill & Milinda Gates Foundation It’s the second joint activity involving both parties in the area of family planning, along with the collaboration on The Challenge Initiative (TCI) ▪ Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene, an Investigational Hormone-Free, Monthly Contraceptive ▪ Licensing Agreement $310 Mn October 2020 Daré Bioscience 41 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

42. 4.2.1 Bayer (continued) Revenues ($Bn), 2020-2030 According to Bayer's 2020 financial report, the company had sales of $45.5 Bn in 2020 ▪ In 2020, Pharmaceuticals accounted for approximately 47% of Bayer's total revenue ▪ 70.9 70.3 This includes medications for various therapeutic areas such as cardiology, oncology, women's health, ophthalmology, and specialty pharmaceuticals ▪ 63.3 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 1 2 3 4 Illustrative Illustrative 42 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

43. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Cancer Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 43 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

44. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 44 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

45. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 45 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

46. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 46 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

47. South Africa Contraceptive Device Market Analysis 5. Reimbursement Scenario

48. 5.1 Reimbursement Regulation Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the US cancer market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many cancer treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for cancer treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 48 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

49. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover certain preventive services, including cancer screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as cancer Reimbursement for New Treatments: Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 49 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential

50. 5.1 Reimbursement Regulation (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities  Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 50 A Sample Report on South Africa Contraceptive Device Market Analysis I Confidential